AT1 receptor blockade utilizing candesartan stimulates angiogenesis through the regulation of vascular endothelial factor (VEGF) and offers protection in animal models of ischemic retinopathy (Shanab et al., 2015) and stroke (Guan et al., 2011). The gene discussed is AGTR1; the disease is Stroke.